BioSpace News Archive

OnPoint Surgical is revolutionizing spinal surgery, including deformity correcting, minimally invasive and endoscopic spine procedures.

Amyris, Inc. (Nasdaq: AMRS), today announced it has entered into a 50:50 joint venture arrangement with ImmunityBio, Inc. (Nasdaq: IBRX), a clinical-stage immunotherapy company, to accelerate the commercialization of a leading next-generation COVID-19 vaccine.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the third quarter of 2021 on Monday, November 15, 2021 after the close of trading on the U.S. financial markets

Goldfinch Bio today provided an update on TRACTION-2, its ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN).

Gyroscope Therapeutics Holdings plc today announced that Sanofi, a global biopharmaceutical company, has committed to invest up to USD $60.0 million (GBP £44.5 million) in equity in Gyroscope.

Alpine Immune Sciences, Inc. today announced a presentation in a Plenary session of the American College of Rheumatology (ACR) Convergence 2021 Annual Meeting.

ReCode Therapeutics today announced that Company leadership will participate in two upcoming virtual investor conferences in November: 2021 Stifel Healthcare Conference Format: Live Presentation Date: Monday, November 15, 2021 Time: 4:40 p.m.

DiaMedica Therapeutics Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted and concluded that DiaMedica “may proceed” with the proposed clinical investigation using its amended protocol adding stroke recurrence as a second independent primary endpoint to its Phase 2/3 ReMEDy2 trial

Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will participate in an upcoming virtual investor conference.

Investigators, led by CancerCare Manitoba researchers and BioMark collaborators, Drs. Donald W. Miller and Marshall Pitz, will be presenting 2 posters on ongoing pre-clinical and clinical research work related to a novel treatment monitoring tool and a potential therapeutic target for glioblastoma (GBM) patients using proprietary brain delivery mechanism.